US FDA Advisory Committee votes in favour that data support the efficacy and safety of remestemcel-L (Ryoncil™) in the treatment of children with steroid-refractory acute graft versus host disease

Remestemcel-L is an investigational allogeneic cell therapy, comprising culture- expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. A final FDA decision regarding its approval is awaited.

Source:

Biospace Inc.